Key facts
- This page summarizes Benjamin Halladay's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Mar 2023, 09:21.
Benjamin Halladay - 14 Mar 2023 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ESPR
- Reported as of
- 14 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Mar 2023, 09:21:21 UTC
- Prior SEC filing
- 12 Dec 2022
- Next SEC filing
- 15 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sheldon L. Koenig, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Benjamin Halladay filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 15 Mar 2023.
Change
- Previous filing in this sequence was filed on 12 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ESPR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +9,200
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 73,936
- Date
- 14 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ESPR
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +39,000
- Change %
- Price
- $0.000000
- Shares after
- 39,000
- Date
- 14 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 39,000
- Exercise price
- $4.02
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Such award will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service.
Footnote F2
Consists of 73,936 shares of common stock held, including 2,306 shares recently acquired in Esperion's Employee Stock Purchase Plan.
Footnote F3
Such options will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service.